TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01999413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMEGAVEN
Description: AML Study treatment induction phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: AML Study treatment induction phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: AML Study treatment induction phase
Study: NCT01545908

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal transplant
Description: Participants in this arm undergo 6 retention enemas,using stool specimen prepared from a healthy, screened unrelated donor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo enema
Description: Patients will receive placebo enema, week 1, week 2, week 3, week 4, week 5, week 6
Study: NCT02787434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prostate Cancer Screening Decision Aid
Description: All patients recruited to the study will receive the PCSPrep decision aid. There is only 'study arm.' The Clinical Research Coordinator (CRC) will provide the patient with an iPad to complete the pre-test, PCSPrep and post-test. Individuals will see the survey questions on screen and will hear accompanying audio through headsets. Participants will: (1) be introduced to PCSPrep and the menu of activities/topics; (2) enter information about themselves for personal tailoring (e.g., risk factors); (3) participate in a values-clarification exercise to rate the personal importance of varied courses of action (i.e., pros/cons of PCS); (4) receive a printout with an individualized plan for discussing PCS with their primary care provider.
Study: NCT02280928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercise
Description: Balance activities, using a task-oriented approach, progress participants from body stability, to body stability plus hand manipulation, then body transport, and finally body transport plus hand manipulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercise
Description: Balance activities, using a task-oriented approach, progress participants from body stability, to body stability plus hand manipulation, then body transport, and finally body transport plus hand manipulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training involves executive function, attention, and working memory. Examples of cognitive training include finding the exit to a maze, calculation, visual-spatial skills, Sudoku, Stroop color-word task, word search, spot the differences, visual discrimination, and memory scanning skills.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training involves executive function, attention, and working memory. Examples of cognitive training include finding the exit to a maze, calculation, visual-spatial skills, Sudoku, Stroop color-word task, word search, spot the differences, visual discrimination, and memory scanning skills.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task cognitive-cognitive training
Description: The Dual-task cognitive-cognitive training involves applying two cognitive tasks at the same time.
Study: NCT04341597

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cervical ultrasound
Description: All volunteer patients for whom a cervical ultrasound is indicated will have with a first operator the performing the usual technic, and with a second operator performing the trans perineal technic without being aware of the first measurement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical ultrasound
Description: All volunteer patients for whom a cervical ultrasound is indicated will have with a first operator the performing the usual technic, and with a second operator performing the trans perineal technic without being aware of the first measurement.
Study: NCT03114982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP608
Description: Preparation of the Oka/SK strain of live, attenuated varicella virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP608
Description: Preparation of the Oka/SK strain of live, attenuated varicella virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP608
Description: Preparation of the Oka/SK strain of live, attenuated varicella virus

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax
Description: Preparation of the Oka/Merck strain of live, attenuated varicella virus
Study: NCT05080179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Benefit/Social Norm
Description: As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. and Over 650,000 Pennsylvanians have already downloaded the app!

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Benefit/No Social Norm
Description: As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. They will not read any information about the number of Pennsylvanians who downloaded the app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Other Benefit/Social Norm
Description: As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. and Over 650,000 Pennsylvanians have already downloaded the app!

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Other Benefit/No Social Norm
Description: As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. They will not read any information about the number of Pennsylvanians who downloaded the app.
Study: NCT02624401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of saline (Ringer's Acetate)
Study: NCT03566693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM System
Description: continuous glucose monitor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood glucose meter
Description: Blue-tooth enabled blood glucose meter
Study: NCT01552928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagrelide 0.5 mg
Description: 0.5mg Anagrelide single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagrelide 2.5 mg
Description: 2.5mg Anagrelide single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg Moxifloxacin single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Anagrelide placebo + Moxifloxacin placebo single oral dose
Study: NCT00654511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 1mcg/kg, Intravenous (IV)
Study: NCT03570827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03375255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP-5051
Description: Single dose of SRP-5051 administered as an intravenous (IV) infusion.
Study: NCT00075491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study: NCT00654511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 2mcg/kg, Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine, 2mcg/kg, Intravenous (IV)
Study: NCT00075491

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02082158

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study Procedures
Description: Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study Procedures
Description: Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Procedures
Description: Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Procedures
Description: Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Procedures
Description: Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Procedures
Description: Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.
Study: NCT01443416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal conjugate vaccine
Description: The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age.
Study: NCT03126656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate
Description: just hypogonadic patients enrolled received hormone replacement therapy with testosterone undecanoate 1000 mg/4ml intramuscular (IM) at baseline, after 6 weeks and 12 weeks after the first evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate
Description: just hypogonadic patients enrolled received hormone replacement therapy with testosterone undecanoate 1000 mg/4ml intramuscular (IM) at baseline, after 6 weeks and 12 weeks after the first evaluation
Study: NCT04126239

Intervention type: OTHER
Intervention: Online survey - questionnaire
Description: Online survey - questionnaire

Intervention type: OTHER
Intervention: Online survey - questionnaire
Description: Online survey - questionnaire
Study: NCT01129739

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine A (CsA)
Description: CsA 5mg/kg po for 6 months
Study: NCT03670134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Nvision VLE Imaging System
Description: Volumetric laser Endomicroscopy (VLE) will be performed by using the Nvision VLE Imaging System (Nine Point Medical, MA) consists of an imaging console, monitor and optical probe. The optical probe is centered by a balloon (diameter: 14 mm, 17 mm, 20 mm; length: 6 cm) that is deployed through a diagnostic gastroscope's instrument channel. Imaging is performed by automatic helical pullback of the probe from the distal to the proximal end of the balloon over 90 seconds.
Study: NCT02800031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography
Study: NCT00240617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sumatriptan succinate/naproxen sodium
Description: comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match
Study: NCT02182414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 207127 NA (TF-I)
Description: 200 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA (TF-II)
Description: 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA (TF-II)
Description: 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA (TF-II)
Description: 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA delayed release
Description: 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA delayed release
Description: 400 mg tablet
Study: NCT04736355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB
Description: oral, for 24 weeks
Study: NCT02182414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA delayed release
Description: 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA extended release (10% HPMC)
Description: 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA extended release (10% HPMC)
Description: 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA extended release (10% HPMC)
Description: 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA extended release (15% PEO)
Description: 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA extended release (15% PEO)
Description: 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA extended release (15% PEO)
Description: 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA extended release (20% HPMC)
Description: 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA extended release (20% HPMC)
Description: 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA extended release (20% HPMC)
Description: 400 mg tablet
Study: NCT04038229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced recovery pathway
Description: The applied protocol include psychological screening for yellow flags, preoperative gabapentin, peroperative multimodal preemptive management and postoperative holistic evaluation short -and long term
Study: NCT02057692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM001
Description: LUM001 administered orally
Study: NCT00654511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine, 4mcg/kg Intravenous (IV)
Study: NCT03017924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q collar
Description: q-collar concussion prevention device
Study: NCT03314519

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography by experienced anaesthesiologist
Description: Use ultrasound image of lung at upper and lower lobe to detect lung collapse and compare grading of lung collapse by surgeon as gold standard
Study: NCT02057692

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally
Study: NCT06037824

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: cryotherapy was added to rehabilitation\*. One group received compressive cryotherapy and the other conventional cold pack cryotherapy.~\* rehabilitation includes (=classic rehabilitation) passive and active of mobilization of knee and patella, treat arthrogenic muscular inhibition, learn to lock the quadriceps, progressive muscular strengthening of the periarticular muscles of the knee, stretching of the quadriceps and the posterior muscular chain, proprioceptive exercises with bi- and unipodal balance, transfer of support and resumption of the walking pattern.
Study: NCT03314519

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic bronchoscopy for double lumen tube's position
Description: Use fiberoptic bronchoscope via double lumen tube to detect optimum position of double lumen tube and record grading of lung collapse by surgeon as gold standard
Study: NCT01540916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increase minute ventilation
Description: Respiratory rate will be increase in order to have a 30% increase of minute ventilation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decrease minute ventilation
Description: Respiratory rate will be decrease in order to have a 30% decrease of minute ventilation
Study: NCT06037824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: cryotherapy was added to rehabilitation\*. One group received compressive cryotherapy and the other conventional cold pack cryotherapy.~\* rehabilitation includes (=classic rehabilitation) passive and active of mobilization of knee and patella, treat arthrogenic muscular inhibition, learn to lock the quadriceps, progressive muscular strengthening of the periarticular muscles of the knee, stretching of the quadriceps and the posterior muscular chain, proprioceptive exercises with bi- and unipodal balance, transfer of support and resumption of the walking pattern.
Study: NCT00590018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone taper (100mg/m2/day --\> 25mg/m2/day) over 5 days intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 5 days intravenously.
Study: NCT03930212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: received rectal progesterone suppositories 400 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: received placebo suppositories rectally once daily.
Study: NCT00344149

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab (Mabthera)
Description: I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (Mabthera)
Description: I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
Study: NCT02473159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
Study: NCT00941616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostate®
Description: 80 IU vWF/kg administered as a bolus intravenous infusion on Day 1 and approximately Day 180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostate®
Description: Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostate®
Description: Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostate®
Description: Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
Study: NCT01463904

Intervention type: PROCEDURE
Intervention: SADI-S 250
Description: Single-Anastomosis Duodeno-Ileal bypass with Sleeve gastrectomy
Study: NCT04426825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg intravenously on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Study: NCT03584646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nokia GO Wearable StepTracker
Description: All participants will be provided with a Nokia GO step tracker to monitor daily step counts. The device is not subject to FDA regulation.
Study: NCT01620632

Intervention type: PROCEDURE
Intervention: Laparoscopy assisted ERCP
Description: Patients will go the the Operating room and through laparoscopy will have an ERCP for their medical indication.
Study: NCT04137276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin C, vitamin B1
Description: vitamin C 1,5 g/6 hours IV + thiamine 200 mg/12 hours for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin B1
Description: thiamine 200 mg/12 hours for 3 days
Study: NCT04335266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554
Description: SHR2554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554
Description: SHR2554
Study: NCT00234858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trandolapril/verapamil
Description: 2/180 mg QD with titration if needed at Week 4 to 4/240 mg QD
Study: NCT03207958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: -Given over 1 hour
Study: NCT01529307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS266
Description: TAS266 IV infusions given weekly
Study: NCT00641199

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jarro-Dophilus EPS probiotics
Description: Jarro-Dophilus EPS product 2 capsules twice daily. 4.4 billion live bacteria per capsule.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jarro-Dophilus EPS probiotics
Description: Jarro-Dophilus EPS product 2 capsules twice daily. 4.4 billion live bacteria per capsule.
Study: NCT04377906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modification Lifesyle
Description: high protein-fiber and exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modification Lifesyle
Description: high protein-fiber and exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modification Lifesyle
Description: high protein-fiber and exercise
Study: NCT02512055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Repeated ketamine 2 mg/kg administration intravenously for sedation during each radiotherapy sessions